ProCE Banner Activity


Tissue Is Not Always the Issue: Expanding Armamentarium of Histology-Agnostic Targeted Therapies for Solid Tumors


Watch this on-demand webcast from a June 2023 symposium featuring John Marshall, MD; Chul Kim, MD, MPH; Sapna P. Patel, MD; Neil H. Segal, MD, PhD; Jonathan Trent, MD, PhD; and Nagla Abdel Karim, MD, PhD, to apply practice-changing clinical data and expert recommendations to optimally integrate histology-agnostic therapies into treatment of eligible patients with cancer.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 20, 2023

Expiration: June 19, 2024



Nagla Abdel Karim

Nagla Abdel Karim, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
University of Virginia
Director of Early Therapeutics Program/Phase I Program
Inova Schar Cancer Institute
Fairfax, Virginia

Chul Kim

Chul Kim, MD, MPH

Associate Professor
Department of Medicine, Division of Hematology and Oncology
Georgetown Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

John Marshall

John Marshall, MD

Executive Director 
Medstar Hematology/Oncology
Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC

Sapna P. Patel

Sapna P. Patel, MD

Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Associate Professor, Director of the Uveal Melanoma Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

Neil H. Segal

Neil H. Segal, MD, PhD

Research Director
Associate Attending, Gastrointestinal Oncology Service
Division of Gastrointestinal Oncology
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
Cornell University
New York, New York

Jonathan Trent

Jonathan Trent, MD, PhD

Professor of Medicine
Department of Medical Oncology
Miller School of Medicine
Sylvester Comprehensive Cancer Center
Miami, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Aadi Bioscience, Bayer HealthCare Pharmaceuticals Inc., and Lilly.

Aadi Bioscience

Bayer HealthCare Pharmaceuticals Inc.


Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimally integrate histology-agnostic therapies into treatment of eligible patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions, mutations, and other targetable genomic alterations in patients with malignant 
    solid tumors

  • Appraise emerging clinical efficacy and safety data supporting the use of histology-agnostic therapies in solid tumors

  • Formulate strategies for integrating histology-agnostic agents into the management of eligible patients with cancer based on biomarker assessment, current evidence, as well as expert and guideline recommendations

  • Identify and refer eligible patients with appropriate biomarkers for enrollment in ongoing clinical trials investigating histology-agnostic therapies


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Nagla Abdel Karim, MD, PhD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, G1 Therapeutics, Jazz, Pfizer, Regeneron, Sanofi; researcher: Bristol Myers Squibb, Exelixis, Pfizer.

Chul Kim, MD, MPH: consultant/advisor/speaker: Arcus, AstraZeneca, Daiichi Sankyo, Diffusion, Eisai, Janssen, Jazz, Mirati, Novartis, PierianDX, Regeneron, Sanofi; researcher: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, Genentech, Janssen, Karyopharm, Lyell Immunopharma, Merck, Novartis, Regeneron.

John Marshall, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Caris, Daiichi, Merck, Pfizer, Seagen, Taiho; Chief Medical Officer: Indivumed; advisory board: OnDose, 2Curex.

Sapna P. Patel, MD: consultant/advisor/speaker: Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Delcath, Guidepoint Global, Hexal/Sandoz, Immatics, Immunocore, Novartis, OncoSec, Pfizer, Replimune, Terranova Medica, TriSalus Life Sciences; researcher: Bristol Myers Squibb, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen, Novartis, Provectus, Seagen, Syntrix Bio, TriSalus Life Sciences.

Neil H. Segal, MD, PhD: consultant/advisor/speaker: ABL Bio, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Numab, Puretech, Regeneron, Revitope, Roche/Genentech; researcher: AstraZeneca, Bristol Myers Squibb, Immunocore, Merck, Pfizer, PureTech, Regeneron, Roche/Genentech.

Jonathan Trent, MD, PhD: consultant/advisor/speaker: Aadi, Adcendo, Bayer, Blueprint, Boehringer Ingelheim, Cogent, Deciphera, Foghorn.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 20, 2023, through June 19, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

Joint Accreditation
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.